KVD900, an oral plasma kallikrein inhibitor, was evaluated in a phase 2, placebo-controlled, double-blind crossover trial in patients with hereditary angioedema (HAE) experiencing mild-to-moderate attacks. Given the lack of a “gold standard,” several patient-reported outcomes (PROs) were collected to capture the patient experience. To read this article in full you will need to make a payment ACAAI Member Login ACAAI Member, full access to the journal is a member benefit.
